Neumora Therapeutics (NMRA) Corporate presentation summary

Mission and leadership

• Focused on developing next-generation, brain-penetrant therapies to improve outcomes and quality of life for patients with neurological and psychiatric disorders.

• Led by experienced executives and board members with backgrounds in major pharmaceutical and biotech companies.

Addressing unmet needs in large markets

• Targeting neurodegenerative, neuropsychiatric, and metabolic diseases, which impact millions in the U.S. and globally.

• Aims to provide novel mechanisms, improved safety, and better tolerability, especially for elderly and high-risk populations.

Pipeline and clinical programs

• Advancing three core franchises: neurodegenerative (NMRA-511, NMRA-GCASE, NMRA-CK18), neuropsychiatric (Navacaprant, NMRA-898, NMRA-861), and metabolic (NMRA-215, undisclosed program).

• Multiple programs in Phase 1 and 2, with key milestones expected in 2026 and 2027.